Modality
ADC
MOA
CAR-T BCMA
Target
TROP-2
Pathway
mTOR
ObesityPAHMDD
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
~Jan 2018
→ ~Apr 2019
NDA/BLA
~Jul 2019
→ ~Oct 2020
Approved
Jan 2021
→ Dec 2027
ApprovedCurrent
NCT03349244
297 pts·Obesity
2021-08→2027-01·Active
NCT04726881
1,709 pts·Obesity
2021-01→2027-12·Not yet recruiting
2,006 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2027-01-2210mo awayPh3 Readout· Obesity
2027-12-121.7y awayPh3 Readout· Obesity
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2027-01-22 · 10mo away
Obesity
Ph3 Readout
2027-12-12 · 1.7y away
Obesity
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03349244 | Approved | Obesity | Active | 297 | SRI-4 |
| NCT04726881 | Approved | Obesity | Not yet recr... | 1709 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 |